Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...

Wide receiver Emeka Egbuka was having a breakout rookie season before a hamstring injury. Here's what we know before the Buccaneers face the Lions.

“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...

T-DXd significantly improved IDFS and reduced the risk of invasive disease or death by 53% compared to T-DM1 in high-risk, HER2-positive breast cancer patients. The trial demonstrated superior ...

A New Era in the Treatment of Muscle Invasive Bladder Cancer. Discussant of LBA2 - Perioperative (Periop) Enfortumab Vedotin ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...

The name Wallace Unamba didn’t come up once during UVA Football coach Tony Elliott ’s Tuesday presser, which stands out, ...

U.S. stock buybacks are projected to hit record highs in 2025, potentially exceeding $1.8 trillion. Learn more about SPY ...

Practise subject-wise RBI Grade B Important Questions and Answers for Phase 1 covering English, Reasoning, Quantitative ...

This news release has been reviewed and approved by Mr Stephen Holley, (BSc (Hons), ACSM, MSc, MSCM, CEng FIMMM), Technical Services Manager for Cornish Metals Inc, who is the designated QP for the ...